Actavis launches Kadian authorized generic
MORRISTOWN, N.J. — Actavis has launched an authorized generic drug for treating pain, the company said.
The drug maker announced Friday that it had started shipping morphine sulfate extended-release capsules, an authorized generic version of Kadian, which it also manufactures. The authorized generic product was launched on the same day as Watson Pharmaceuticals’ generic version.
Authorized generics are branded drugs marketed under their generic names at a reduced price, either by the branded drug’s manufacturer or a third-party company through a contractual agreement, as a way to provide the branded manufacturer an additional means of competing against the generic manufacturer during the latter’s legally mandated, 180-day market-exclusivity period.
Kadian had sales of $275 million during the 12-month period ended in September, according to IMS Health.
NACDS bolsters staff with new communications manager
ALEXANDRIA, Va. — The National Association of Chain Drug Stores has hired healthcare policy reporter Ben Moscovitch to serve as communications manager.
Moscovitch joins NACDS’ marketing, communications and media relations department, and will report to Chrissy Kopple, VP media relations. Prior to joining NACDS, Moscovitch served as the managing editor for Inside Washington Publishers’ FDA Week and wrote for the Inside Health Policy website. In this capacity, Moscovitch reported on issues that relate directly to pharmacy and to other aspects of healthcare delivery.
“Ben will bring additional expertise and professionalism to an NACDS team that dedicates its talent and tenacity to advancing community pharmacy every day,” stated NACDS president and CEO Steve Anderson. “At the heart of the NACDS brand is a commitment to talking externally and with passion about the work of the people of community pharmacy, and we look forward to the unique perspective that Ben will bring to this effort as a journalist and as a creative communicator.”
Previously, Moscovitch served as a reporter for Exchange Monitor Publications, and as a writer in the government affairs office of Underwriter Labs. He also has written articles for the Foreign Policy Association, focusing on Middle East issues.
Study: Pfizer, Bristol-Myers Squibb drug for internal blood clots not superior to enoxaparin
NEW YORK — A drug under development by Pfizer and Bristol-Myers Squibb for preventing internal blood clots failed to show superiority over a treatment already on the market, the companies said Monday.
The two drug makers announced Monday results of the phase-3 "ADOPT" study, which was designed to compare the safety and effectiveness of Eliquis (apixaban) with enoxaparin in preventing venous thromboembolism in patients with acute medical illness. Sanofi sells enoxaparin under the brand name Lovenox, and it is available as a generic.
Pfizer and Bristol said Eliquis did not show superiority over enoxaparin in preventing VTE, and while patients taking apixaban showed a 13% lower rate of adverse side effects than patients taking enoxaparin followed by placebo, that result was not statistically significant.
The drug is approved in the European Union for preventing VTE in adults who have undergone total hip or knee-replacement surgery.